NCT06783257View on ClinicalTrials.gov

Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Peptic Ulcer Bleeding
Interventions
DRUG

Vonorasan fumarate injection1

40 mg (20 mg bid, 6 hours apart, Day1) + 20 mg (Day2\&3, q24h), ivd, 30 min, administered for 3 days

DRUG

Vonorasan fumarate injection2

40mg（Day1）+20mg（Day 2\&3），ivd，30min，q24h，administered for 3 days

DRUG

Esomeprazole sodium for injection

80mg，iv，30±3min； Followed by 8 mg/h, ivd, 71.5 h

All Listed Sponsors
lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY